The pharmaceutical company has set the range for its initial public offering, which will see Johnson & Johnson become a notable shareholder.
US-based pharmaceutical company Minerva Neurosciences set the range of its initial public offering at $10-12 yesterday, which would result in an IPO sized between $54.5m and $65.4m.
Minerva, which is working on drugs to treat central nervous system diseases, will issue approximately 5.45 million shares in the offering. Underwriters Jeffries, Baird and JMP Securities have the 30-day option to sell a further 818,000 shares, which would boost the size of the IPO by between $8.2m and $9.8m.
Janssen Pharmaceutica plans…
